PET/MR bests PET/CT in identifying prostate cancer recurrence

06/21/2013 | Medscape (free registration)

PET/MR imaging with 11C-choline for restaging of prostate cancer was well-tolerated and able to identify more small local recurrences than PET/CT, according to a study presented at the SNMMI Annual Meeting. The radiation dose exposure with PET/MR imaging is about 80% lower than with PET/CT, researchers said, suggesting the approach may be particularly beneficial for patients who need a number of tests.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health